Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Chemotherapy
98%
Malignant Neoplasm
55%
Docetaxel
43%
Neoplasm
40%
Overall Survival
39%
Triple Negative Breast Cancer
34%
Metastatic Breast Cancer
32%
Cisplatin
30%
Folinic Acid
28%
Abdominal Cancer
27%
Disease
27%
Fluorouracil
25%
Epirubicin
23%
Trastuzumab
23%
Progression Free Survival
23%
Non Small Cell Lung Cancer
23%
Doxorubicin
22%
Neutropenia
22%
Paclitaxel
20%
Anthracycline
17%
Epidermal Growth Factor Receptor
16%
Gemcitabine
16%
Adverse Event
15%
Febrile Neutropenia
15%
Cyclophosphamide
15%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
14%
Second-Line Chemotherapy
13%
Nanoparticle
13%
First-Line Chemotherapy
13%
Tolerability
12%
Taxane
12%
Tumor Growth
11%
Poloxamer
11%
Anemia
11%
Placebo
11%
Oxaliplatin
10%
Metastasis
10%
Capecitabine
9%
Filgrastim
9%
Heat Shock Protein 90
9%
Deguelin
9%
Pertuzumab
9%
Granulocyte Colony Stimulating Factor
8%
Breast Carcinoma
8%
Prodrug
8%
Monotherapy
7%
Neuropathy
7%
Hormone Receptor
7%
Irinotecan
7%
Keyphrases
Chemotherapy
56%
Docetaxel
42%
Metastatic Breast Cancer
36%
Phase II Study
33%
Breast Cancer
32%
Overall Survival
31%
Human Epidermal Growth Factor Receptor 2 (HER2)
28%
Leucovorin
28%
Triple-negative Breast Cancer
27%
Cisplatin
27%
5-fluorouracil (5-FU)
27%
Breast Cancer Patients
25%
Epirubicin
25%
Cancer Stem-like
24%
Neutropenia
23%
Heat Shock Protein 90 (Hsp90)
22%
Confidence Interval
22%
Polymorphism
21%
Meta-analysis
21%
Prognostic Factors
20%
Korean Population
19%
Cancer Stem Cells
18%
Metastatic Gastric Cancer
18%
HER2-positive Breast Cancer
18%
Advanced Gastric Cancer
18%
Breast Cancer Risk
17%
Doxorubicin
17%
Paclitaxel
16%
Gemcitabine
16%
Early Breast Cancer
16%
Trastuzumab
15%
Breast Cancer Recurrence
15%
Cyclophosphamide
15%
Lung Cancer
15%
Stem Cells
15%
Combination Chemotherapy
15%
Tumor
15%
Adjuvant Therapy
14%
Anthracyclines
14%
Non-small Cell Lung Cancer (NSCLC)
14%
Second-line Chemotherapy
14%
Febrile Neutropenia
14%
Overall Response Rate
14%
Partial Response
14%
Adverse Events
13%
Tolerability
13%
Elderly Patients
13%
First-line Chemotherapy
13%
Tumor Growth
13%
Phase II Trial
13%
Medicine and Dentistry
Breast Cancer
67%
Chemotherapy
40%
Neoplasm
33%
Overall Survival
29%
Cancer Stem Cell
27%
Non Small Cell Lung Cancer
27%
Malignant Neoplasm
26%
Triple Negative Breast Cancer
26%
Cancer Cell
20%
Prognostic Factor
18%
Epidermal Growth Factor Receptor
16%
Progression Free Survival
15%
Metastatic Carcinoma
13%
Meta-Analysis
13%
Abdominal Cancer
13%
Second-Line Chemotherapy
12%
Disease
10%
Tumor Progression
10%
Programmed Cell Death
10%
Folinic Acid
9%
Recurrent Disease
9%
Estrogen Receptor
8%
Receptor
8%
Hazard Ratio
8%
Hormone Receptor
8%
Docetaxel
7%
Elderly Patient
7%
Metastatic Breast Cancer
7%
Vasculotropin
7%
Receptor Expression
6%
Flubendazole
6%
Angiotensin II
6%
Ipatasertib
6%
Tamoxifen
6%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
6%
Pemetrexed
6%
Fluorouracil
6%
Paclitaxel
6%
Messenger RNA
6%
Placebo
6%
Cancer Growth Factor
6%
Small Cell Lung Cancer
6%
First-Line Chemotherapy
6%
Multivariate Analysis
6%
Disease Free Survival
6%
Cancer Therapy
5%
Mesenchymal-Epithelial Transition
5%
Adenocarcinoma
5%
Biliary Tract Cancer
5%
Aldehyde Dehydrogenase Isoenzyme 1
5%